2022 Venom Evolution, Function and Biomedical Applications GRC/GRS

2022 毒液进化、功能和生物医学应用 GRC/GRS

• 批准号: 10391650
• 负责人: Mande N. Holford
• 金额: $ 3万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-12-01 至 2022-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10391650
• 关键词: Address; Animals; Anticoagulation; Applied Research; Area; Basic Science; Biological Models; Biology; Biomedical Research; Biotechnology; Breathing; Captopril; Categories; Collaborations; Communication; Communities; Complex; Coronary; Coupled; Development; Diabetes Mellitus; Discipline; Ecology; Economics; Epilepsy; Evolution; Fostering; Future; Gender; General Population; Genomics; Goals; Health; Human; Human Pathology; Hypertension; Iceberg; Impairment; Industry; Ion Channel; Ion Channel Gating; Knowledge; Life; Ligands; Link; Manuscripts; Medicine; Methodology; Molecular; Molecular Structure; Molecular Target; National Center for Complementary and Integrative Health; Natural Sciences; Outcome; Pain; Pain management; Participant; Peptides; Pharmaceutical Preparations; Pharmacology; Physiological; Postdoctoral Fellow; Predatory Behavior; Prevention strategy; Protein Engineering; Proteomics; Publications; Research; Route; Science; Scientist; Societies; Source; Study models; Syndrome; Targeted Toxins; Technology; Therapeutic; Time; Toxin; Translating; Trees; Venoms; World Health Organization; bivalirudin; cohesion; drug development; drug discovery; early-career faculty; economic impact; eptifibatide; exenatide; frontier; global health; graduate student; health economics; human disease; innovation; interdisciplinary approach; meetings; neglected tropical diseases; non-opioid analgesic; novel; novel therapeutics; programs; receptor; research and development; response; socioeconomics; symposium; therapeutic development; tirofiban; tool; translational applications; voltage; ziconotide

Summary/Abstract Animal venoms are among the most complex natural secretions known, comprising a mixture of bioactive compounds often referred to as toxins. Despite their complexity, the molecular structure and targets of toxins, which include receptors and voltage- and ligand-gated ion channels, are relatively conserved throughout the animal kingdom. These features make venom an extremely successful evolutionary innovation whose components are ideal candidates for discovery and development of therapeutics to treat a wide range of human pathologies. Currently, six venom-derived peptides are commercially available drugs: ziconotide for pain; exenatide for diabetes; bivalirudin for anticoagulation; captopril for hypertension; and eptifibatide and tirofiban for coronary syndrome. Venom research is growing exponentially, as evidenced by the increase in venom publications, symposia, biomedical applications and biotech startup companies, leading to important socio- economic impacts on society. As a consequence, the World Economic Forum recently designated Venomics as one of the four most promising frontiers of science, and the World Health Organization classified snakebite as a “Category A Neglected Tropical Disease” and launched a global strategy for prevention and control of snakebite envenoming. Yet, the full potential of venom remains untapped due to a lack of knowledge on many venomous animals and a scarcity of opportunities to create a cohesive research community focused on the diversity of venom. Venom occurs so broadly across the animal tree of life that no single conference links experts in the basic and applied sciences of venomous animals to those investigating the physiological and pharmacological applications of venom. The 2022 Gordon Research Conference and Seminar on Venom Evolution, Function and Biomedical Applications (Venoms-GRC/GRS) aims to overcome these hurdles by coalescing an interdisciplinary group of academic and industry professionals to address venom as both a global health problem and a route to innovation in health solutions, including alternative, non-opioid pain management strategies. Our goals are to evaluate needs and challenges pertaining to drug discovery and development, identify future goals for venom research that will enable the field to grow and impact biomedical research and drug development and, via a special issue of manuscripts from collaborations fostered at the conference, disseminate innovative future directions in the venom field. The conference chairs are making significant efforts to invite a culturally, ethnically, and gender diverse group of 150 established and early-career faculty, postdoctoral fellows, and graduate students to the 2022 Venoms-GRC/GRS. Our program will foster a community of experts focused on complementary and integrative topics in venom drug discovery and development – key issues that are relevant to NCCIH.

摘要/摘要 动物毒液是已知的最复杂的天然分泌物之一，包含生物活性物质的混合物 化合物通常被称为毒素。尽管毒素的分子结构和目标很复杂， 其中包括受体以及电压门控离子通道和配体门控离子通道，在整个过程中相对保守 这些特征使毒液成为一种极其成功的进化创新。 成分是发现和开发治疗广泛人类的疗法的理想候选者 目前，有六种毒液衍生肽已上市销售：齐考诺肽用于止痛； 艾塞那肽用于治疗糖尿病；比伐卢定用于抗凝；卡托普利用于治疗高血压；依替巴肽和替罗非班； 对于冠状动脉综合征的毒液研究正在呈指数级增长，毒液的增加就证明了这一点。 出版物、研讨会、生物医学应用和生物技术初创公司，导致重要的社会 因此，世界经济论坛最近将毒组学指定为 四个最有前途的科学前沿之一，世界卫生组织将蛇咬伤列为 被列为“A类被忽视的热带病”，并启动了预防和控制该病的全球战略 然而，由于对许多方面缺乏了解，毒液的全部潜力仍未得到充分利用。 有毒动物和缺乏机会来创建一个有凝聚力的研究社区，专注于 毒液的多样性广泛存在于动物生命之树中，以至于没有一个会议将专家联系起来。 在有毒动物的基础和应用科学中，研究生理和 2022年戈登毒液研究会议暨研讨会。 进化、功能和生物医学应用 (Venoms-GRC/GRS) 旨在通过以下方式克服这些障碍 联合学术界和行业专业人士组成的跨学科小组，将毒液视为全球性问题 健康问题和健康解决方案创新之路，包括替代性非阿片类疼痛管理 我们的目标是评估与药物发现和开发相关的需求和挑战， 确定毒液研究的未来目标，使该领域能够发展并影响生物医学研究和 药物开发，并通过会议上建立的合作手稿特刊， 传播毒液领域的创新未来方向。会议主席正在做出重大努力。 邀请 150 名在文化、种族和性别上多元化的已任职教师和早期职业教师， 2022 年 Venoms-GRC/GRS 的博士后研究员和研究生我们的计划将培养 专家社区专注于毒液药物发现和毒液药物发现方面的补充和综合主题 发展——与 NCCIH 相关的关键问题。